United Microelectronics Corporation enters the week in an uncomfortable spot: the stock has shed 17% over the past month, a CFO sold nearly $9 million worth of shares close to recent highs, and borrowing costs have more than doubled week-on-week — all while the analyst consensus remains stubbornly bullish.
The insider signal is the sharpest data point this week. UMC's CFO sold 1.9 million shares on July 13 at TWD 154.89 — a price roughly 30% above where the stock trades today at TWD 119. That single transaction accounted for nearly all of the TWD-equivalent $9.2 million in net selling recorded over the past 90 days. A Vice President added a token sale at the end of June. Neither trade carries a high significance score, but the timing — near what proved to be a local peak — is notable context as the stock continues to slide.
The lending market tells a more relaxed story, though borrowing costs are creeping higher. Availability is extraordinarily loose at roughly 2,949% — meaning shares available to borrow dwarf the current short position by nearly 30 times. That's well above the 52-week tightest reading of around 19%, and short interest itself remains negligible, under 1% of free float. Availability has barely moved week-on-week, confirming there is no meaningful squeeze dynamic in play. Cost to borrow has, however, more than doubled over the past week to 1.58%, up from around 0.71% a week ago. The move is small in absolute terms but marks the fastest weekly acceleration since early July — worth tracking if it continues.
The Street remains constructive despite the price action. Twelve analysts rate UMC a buy against six holds, with a consensus price target around TWD 129 — implying roughly 9% upside from current levels. No recent rating changes appear in the data, so the bullish skew predates the month's decline. What supports the bull case structurally is UMC's factor profile: EPS momentum ranks in the 92nd–94th percentile over both 30- and 90-day windows, and EPS surprise sits in the 91st percentile — meaning the company has been beating estimates convincingly. Analyst recommendation divergence ranks at the 100th percentile, which simply reflects the lopsided buy/hold split. On valuation, the trailing P/E has compressed sharply, falling by roughly 10 points over the past 30 days to under 17x. EV/EBITDA has also eased, down about 1 point over the same period to 9.7x — the stock is cheaper than it was a month ago, though the price action suggests the market isn't yet treating that as a catalyst. The ORTEX short score is a reassuring 27.4 — low and stable — consistent with a name where short sellers are not pressing the thesis.
The most recent earnings print on July 29 produced a familiar pattern: the stock fell 3% on the day, then recovered 7.5% over the following five sessions. The prior quarter's release in late April triggered a 2.9% gain on the day and a 21.7% rally over five days. Two data points don't make a trend, but the directional read — initial weakness, subsequent recovery — is worth bearing in mind as the next earnings date approaches on October 28.
With the stock down sharply, costs to borrow rising from a low base, and the CFO's July sale now sitting well in the money for whoever bought those shares from him, the October earnings release is shaping up as the clearest near-term test of whether analyst optimism on UMC's earnings trajectory is still warranted.
See the live data behind this article on ORTEX.
Open 2303 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
